文章核心观点 - 公司宣布基于遗传算法的区块链共识算法 [1][2][3] - 该算法可提高共识效率、区块生成和计算效率 [3] - 未来公司将继续优化联盟链共识机制,推动区块链技术在更多领域的应用 [4] 公司概况 - 公司是全球领先的全息增强现实(AR)技术提供商 [5] - 公司的业务和全息AR技术包括全息AR汽车应用、3D全息脉冲激光雷达技术、全息视觉半导体技术、全息软件开发、全息AR广告技术等 [5]

CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced the introduction of geneType's suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType's recent expansion to the US market under its partnership with health and wellness technology leader Stayhealthy, Inc ("Stayhealthy"), t ...

CHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling ...

CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company’s portfolio o ...

CHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assessment product series. GeneType's multi-patented, clinically validated tests will now be performed by Gene by Gene, a premier specialty genetic laboratory based in Houston, Texas, a state- ...

A joint investigation into a data breach at DNA testing company has been launched by UK and Canadian watchdogs. The Information Commissioner's Office (ICO) and the Office of the Privacy Commissioner of Canada (OPC) announced the investigation into the October 2023 incident. US-based genetics company 23andMe analyses its customers' DNA through home saliva collection kits to provide insights on factors such as health and ancestry. According to the company's website, it has sold more than 12 million DNA testin ...

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...

PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GeneType")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the Know Your Risk event held yesterday at The Langham Pasadena has set a new standard for women's health initiatives, highlighting the transformative potential of genetic testing and risk assessment. Organized by GeneType and Humanise Health, in partnership with Thermo Fi ...

MELBOURNE, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 30 March 2024 (Q3 FY24). Key highlights: Cash Receipts totalling A$1.8m for the quarter ending March 2024. Launching "Know Your Risk" event in Pasadena Launched targeted digital strategy for California i ...

募集资金 - Genetic Technologies Limited宣布完成了注册发行，每股2美元发行了100万美国存托股份[1] - 公司通过私募发行了未注册的认股权证，每股价格为2美元，有效期为五年[2] - 本次发行筹集的总收入约为200万美元，净收益将用于推动收入、支持销售和营销计划、扩大市场、产品研发等用途[4]